

## NATIONAL INSTITUTE FOR HEALTH AND CARE EXCELLENCE

# **Single Technology Appraisal**


# Tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

## Final Stakeholder List

Compultons	Commentations (no visibit to out mit ou
Consultees	Commentators (no right to submit or
0	appeal)
Company	<u>General</u>
Amgen (tarlatamab)	All Wales Therapeutics and Toxicology
	Centre
Patient/carer groups	<ul> <li>Allied Health Professionals Federation</li> </ul>
Asthma and Lung UK	Board of Community Health Councils in
Black Health Agency for Equality	Wales
Cancer Black Care	British National Formulary
Cancer Equality	Care Quality Commission
Helen Rollason Cancer Charity	Department of Health, Social Services
Independent Cancer Patients Voice	and Public Safety for Northern Ireland
Macmillan Cancer Support	Healthcare Improvement Scotland
Maggie's Centres	Medicines and Healthcare products
Marie Curie	Regulatory Agency
Oncogene-Driven Lung Cancer	National Association of Primary Care
Patient Alliance UK	National Pharmacy Association
Roy Castle Lung Cancer Foundation	NHS alliance
Ruth Strauss Foundation	NHS Confederation
0 (1 A : 11 10 E 1 C	Scottish Medicines Consortium
	Welsh Government
Specialised Healthcare Alliance     Tanguia Canage Care	
Tenovus Cancer Care     Turk Live of Cancer Care	<ul> <li>Welsh Health Specialised Services Committee</li> </ul>
UK Lung Cancer Coalition	Committee
Hoolthoore professional groups	Comparator companies
<ul> <li>Healthcare professional groups</li> <li>Association of Anaesthetists</li> </ul>	Accord Healthcare (carboplatin,
	cisplatin, doxorubicin, epirubicin,
Association of Cancer Physicians     Association of Pagairston, Nurse	etoposide, gemcitabine, irinotecan,
Association of Respiratory Nurse     Specialists	oxaliplatin)
Specialists	Baxter Healthcare (cyclophosphamide,
Association of Surgeons of Great      Britain and Iraland	doxorubicin, mitoxantrone)
Britain and Ireland	CNX therapeutics (gemcitabine)
British Geriatrics Society  Delia la stitute of Delia la succession.	Fresenius Kabi (carboplatin, etoposide,
British Institute of Radiology	gemcitabine, oxaliplatin)
British Oncology Pharmacy	Hospira UK (carboplatin, cisplatin,
Association	gemcitabine, irinotecan, oxaliplatin,
British Psychosocial Oncology Society	vincristine)
British Society of Interventional	•• • • • • • • • • • • • • • • • • •
Radiology	Medac GmbH (doxorubicin, epirubicin, etoposide, irinotecan, oxaliplatin)
British Thoracic Oncology Group	etoposide, iriilotecari, oxalipiatiri)

Final stakeholder list for the appraisal of tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

Issue date: March 2024



#### Consultees Commentators (no right to submit or appeal) **British Thoracic Society** Neon Healthcare (etoposide) **British Transplantation Society** Novartis (topotecan) Cancer Research UK Pfizer (carboplatin, cisplatin, doxorubicin, epirubicin, gemcitabine, Lung Cancer Nursing UK idarubicin, irinotecan, oxaliplatin, National Heart and Lung Institute topotecan, vincristine) NHS Blood and Transplant Sandoz (cisplatin, cyclophosphamide, Primary Care Respiratory Society topotecan) Royal College of Anaesthetists Seacross Pharmaceuticals (doxorubicin, Royal College of General Practitioners epirubicin, irinotecan, oxaliplatin) Royal College of Nursing Servier (irinotecan) Royal College of Pathologists Sun pharma (gemcitabine, irinotecan Royal College of Physicians oxaliplatin) Royal College of Radiologists Teva UK (carboplatin, cisplatin, Royal College of Surgeons vincristine) Royal Pharmaceutical Society Zentiva (daunorubicin) Royal Society of Medicine Society and College of Radiographers Relevant research groups **UK Clinical Pharmacy Association** Cochrane Lung Cancer Group **UK Oncology Nursing Society** Cochrane UK Genomics England **Others** Institute of Cancer Research Department of Health and Social Care MRC Clinical Trials Unit NHS England National Cancer Research Institute National Institute for Health Research Associated Public Health groups **Public Health Wales UK Health Security Agency**

NICE is committed to promoting equality, eliminating unlawful discrimination and fostering good relations between people who share a protected characteristic and those who do not. Please let us know if we have missed any important organisations from the stakeholder list, and which organisations we should include that have a particular focus on relevant equality issues.


### **Definitions:**

### Consultees

Organisations that accept an invitation to participate in the evaluation; the company that markets the technology; national professional organisations; national patient organisations; the Department of Health and Social Care and relevant NHS organisations in England.

Final stakeholder list for the appraisal of tarlatamab for previously treated advanced small-cell lung cancer [ID6364]

Issue date: March 2024



The company that markets the technology is invited to make an evidence submission, respond to consultations, nominate clinical experts and has the right to appeal against the Final Draft Guidance (FDG).

All non-company consultees are invited to submit a statement relevant to the group they are representing, respond to consultations, nominate clinical or patient experts and have the right to appeal against the Final Draft Guidance (FDG).

## Commentators

Organisations that engage in the evaluation process but that are not asked to prepare an evidence submission or statement, are able to respond to consultations and they receive the FDG for information only, without right of appeal. These organisations are: companies that market comparator technologies; Healthcare Improvement Scotland; related research groups where appropriate (for example, the Medical Research Council [MRC]); other groups (for example, the NHS Confederation and the British National Formulary).

All non-company commentators are invited to nominate clinical or patient experts.